SCHEMBL19925071

SCHEMBL19925071

O=S(=O)(Nc1ccc(Cl)c(-c2ccc(F)cc2Cl)n1)c1cccc(N2CCNCC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CB P42338 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
MAPK14 Q16539 4/20 0.37
KCNH2 Q12809 1/20 0.37
HTR2C P28335 2/20 0.36
GHSR Q92847 1/20 0.34
BPTF Q12830 1/20 0.34
CTSS P25774 1/20 0.34
SCN9A Q15858 1/20 0.34
NMT1 P30419 2/20 0.34
PIM1 P11309 2/20 0.34
CCNT1 O60563 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29464363 0.91 ADRB2 (0.41) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19927792 0.91 ADRB2 (0.41) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19968843 0.90 ABL1 (0.38) HTR3EHTR3BALDH1A1HTR3AHTR3D
Hydrochloric Acid SCHEMBL19951324 0.90 ADRB2 (0.42) HTR3EHTR3BALDH1A1HTR3AHTR3D
Hydrochloric Acid SCHEMBL19951387 0.90 ABL1 (0.38) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19925080 0.88 HTR3E (0.43) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19968829 0.86 PTPN11 (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19928383 0.85 GHSR (0.38) ALDH1A1GHSRCTSSSCN9ASLC22A12
Hydrochloric Acid SCHEMBL19951404 0.85 PTPN11 (0.39) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL19925107 0.85 HTR3E (0.38) HTR3EHTR3BALDH1A1HTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN claimed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP claimed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US claimed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US claimed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 EP claimed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US claimed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 WO claimed
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
EP-3504194-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE Novartis AG (CH) 2019-07-03 EP disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed
WO-2018042316-A1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 HTR3E 1719/4885HTR3B 1906/4885ALDH1A1 1455/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 HTR3E 1719/4885HTR3B 1906/4885ALDH1A1 1455/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 HTR3E 1719/4885HTR3B 1906/4885ALDH1A1 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.